Aileron scores $1.1B development pact with Roche

Aileron Therapeutics' stapled peptide platform has won over Roche, which is paying $25 million upfront and up to $1.1 billion more in milestones to explore the potential to deliver a new generation of drugs right to their target. For Aileron, a 2009 Fierce 15 company, the billion-dollar deal represents a key endorsement from one of the industry's most innovative pharma companies. And it's the kind of high-profile pact that is likely to generate plenty more interest from Roche's competition,...